Survival of Human Immunodeficiency Virus–Infected Liver Transplant Recipients
Citations Over TimeTop 1% of 2003 papers
Abstract
Human immunodeficiency virus (HIV) infection has been considered an absolute contraindication to solid-organ transplantation. With immune function restoration possible with highly active antiretroviral therapy (HAART), we evaluated 24 HIV-positive subjects with end-stage liver disease who were undergoing orthotopic liver transplantation (OLTX) after the availability of HAART. The cumulative survival among HIV-positive recipients was similar to that among age- and race-comparable HIV-negative recipients (P=.365, by log-rank test). At 12, 24, and 36 months after OLTX, survival was, respectively, 87.1%, 72.8%, and 72.8% among HIV-positive patients, versus 86.6%, 81.6%, and 77.9% among HIV-negative patients. Survival was poorer among subjects with post-OLTX antiretroviral intolerance (P=.044), a post-OLTX CD4(+) cell count of 400 copies/mL (P=.016), and hepatitis C virus infection (P=.023). These findings suggest that survival of HIV-positive liver transplant recipients does not differ from that of HIV-negative liver transplant recipients, and they suggest that HIV infection should no longer be a contraindication to OLTX. Further prospective studies are warranted.
Related Papers
- → Timed Action of IL-27 Protects from Immunopathology while Preserving Defense in Influenza(2014)75 cited
- → X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology(1991)32 cited
- → VIRAL IMMUNOPATHOLOGY(1985)22 cited
- → Pathology and Immunopathology of Acute and Chronic Hepatitis B(1989)
- [HIV infection. Immunopathology and pathogenesis].(1991)